Monil Shah
Chief Operating Officer chez LTR PHARMA LIMITED
Profil
Monil Shah is the founder of Ventrus Biosciences, Inc. which was founded in 2011.
He held the title of Vice President-Clinical Research & Development from 2011 to 2014.
Currently, Dr. Shah holds three jobs.
He is the Chief Business Officer at Imugene Ltd.
since 2021.
He is also the Chief Development Officer at WindMIL Therapeutics, Inc. and the VP-Operations & Clinical Development at LTR Pharma Ltd., both of which are current positions.
Dr. Shah's former positions include Chief Operating Officer at IRX Therapeutics, Inc. and Chief Operating Officer at Eterna Therapeutics LLC from 2017 to 2018.
Dr. Shah received his undergraduate and doctorate degrees from Rutgers State University of New Jersey.
Postes actifs de Monil Shah
| Sociétés | Poste | Début |
|---|---|---|
| IMUGENE LIMITED | Corporate Officer/Principal | 10/06/2021 |
| LTR PHARMA LIMITED | Chief Operating Officer | - |
WindMIL Therapeutics, Inc.
 WindMIL Therapeutics, Inc. Medical SpecialtiesHealth Technology WindMIL Therapeutics, Inc. operates as a biotechnology company. It develops immunotherapies for the treatment of cancer patients. The company was founded by Ivan Borrello and Kimberly Noonan and is headquartered in Baltimore, MD. | Corporate Officer/Principal | - |
Anciens postes connus de Monil Shah
| Sociétés | Poste | Fin |
|---|---|---|
Eterna Therapeutics LLC
 Eterna Therapeutics LLC Pharmaceuticals: MajorHealth Technology Part of Eterna Therapeutics, Inc., Eterna Therapeutics LLC is a clinical-stage biopharmaceutical company based in New York, NY. The private company is focused on exploring the role that cytokine-based therapy can have on the immune system in treating patients with cancer. Eterna Therapeutics is committed to developing irx-2, a novel cytokine-based therapy, to treat patients with cancer. The active constituents of irx-2, namely interleukin-2 (il-2) and other key cytokines, are postulated to signal, enhance and restore immune function suppressed by the tumor, thus enabling the immune system to attack cancer cells. Eterna Therapeutics is a late clinical-stage biopharmaceutical company focused on il-2 cytokine-based therapies in treating patients with cancer. Eterna Therapeutics was acquired by NTN Buzztime, Inc. on March 25, 2021 for $213.30 million. | Chief Operating Officer | 01/10/2018 |
Ventrus Biosciences, Inc.
 Ventrus Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Ventrus Biosciences, Inc. is a development stage specialty pharmaceutical company engages in development of late-stage prescription drugs for gastrointestinal disorders, specifically hemorrhoidal disease, anal fissures, and fecal incontinence. Its major pharmaceutical progress made in the gastrointestinal therapeutic areas of gastroesophageal reflux, peptic ulcer disease, and inflammatory bowel disease. Ventrus Biosciences products includes VEN 307 (topical diltiazem), is intended to treat pain associated with anal fissures and VEN 308 (topical phenylephrine), is intended to treat fecal incontinence. The company was founded on October 10, 2005 and is headquartered in New York, NY. | Founder | 01/03/2014 |
IRX Therapeutics, Inc.
 IRX Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology IRX Therapeutics, Inc. provides pharmaceutical products. Its therapies are designed to target and restore the immune system in order to improve a patient's response to next-generation cancer vaccines and novel targeted therapeutics. The company was founded in 1994 and is headquartered in New York, NY. | Chief Operating Officer | - |
Formation de Monil Shah
| Rutgers State University of New Jersey | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| IMUGENE LIMITED | Health Technology |
| LTR PHARMA LIMITED | Health Technology |
| Entreprise privées | 4 |
|---|---|
IRX Therapeutics, Inc.
IRX Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology IRX Therapeutics, Inc. provides pharmaceutical products. Its therapies are designed to target and restore the immune system in order to improve a patient's response to next-generation cancer vaccines and novel targeted therapeutics. The company was founded in 1994 and is headquartered in New York, NY. | Health Technology |
Ventrus Biosciences, Inc.
Ventrus Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Ventrus Biosciences, Inc. is a development stage specialty pharmaceutical company engages in development of late-stage prescription drugs for gastrointestinal disorders, specifically hemorrhoidal disease, anal fissures, and fecal incontinence. Its major pharmaceutical progress made in the gastrointestinal therapeutic areas of gastroesophageal reflux, peptic ulcer disease, and inflammatory bowel disease. Ventrus Biosciences products includes VEN 307 (topical diltiazem), is intended to treat pain associated with anal fissures and VEN 308 (topical phenylephrine), is intended to treat fecal incontinence. The company was founded on October 10, 2005 and is headquartered in New York, NY. | Health Technology |
WindMIL Therapeutics, Inc.
WindMIL Therapeutics, Inc. Medical SpecialtiesHealth Technology WindMIL Therapeutics, Inc. operates as a biotechnology company. It develops immunotherapies for the treatment of cancer patients. The company was founded by Ivan Borrello and Kimberly Noonan and is headquartered in Baltimore, MD. | Health Technology |
Eterna Therapeutics LLC
Eterna Therapeutics LLC Pharmaceuticals: MajorHealth Technology Part of Eterna Therapeutics, Inc., Eterna Therapeutics LLC is a clinical-stage biopharmaceutical company based in New York, NY. The private company is focused on exploring the role that cytokine-based therapy can have on the immune system in treating patients with cancer. Eterna Therapeutics is committed to developing irx-2, a novel cytokine-based therapy, to treat patients with cancer. The active constituents of irx-2, namely interleukin-2 (il-2) and other key cytokines, are postulated to signal, enhance and restore immune function suppressed by the tumor, thus enabling the immune system to attack cancer cells. Eterna Therapeutics is a late clinical-stage biopharmaceutical company focused on il-2 cytokine-based therapies in treating patients with cancer. Eterna Therapeutics was acquired by NTN Buzztime, Inc. on March 25, 2021 for $213.30 million. | Health Technology |
